The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Asumrano - Truist Securities - Analyst
: Congrats on the quarter and the beat. This is Asumrano on for Joon. Thanks for taking the question, just a couple from us. FIRDAPSE saw a 25%
growth from last year. How much of that would you say is strength in this quarter versus weakness in last year's 12 due to the change in healthcare
impact?
And then as a follow up, can you remind us what proportion of like FIRDAPSE patients on the tablet formulation versus the oral suspension
formulation.
Thank you.
Question: Asumrano - Truist Securities - Analyst
: Very clear. Thank you. And then just on the proportion of my complications that are on the tablets, the oral suspension formulation.
Question: Asumrano - Truist Securities - Analyst
: You. Very helpful.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 08, 2025 / 12:30PM, CPRX.OQ - Q1 2025 Catalyst Pharmaceuticals Inc Earnings Call
Question: Benjamin Paluch - Citi - Analyst
: This is Benjamin Paluch for Samantha. Thanks for taking the questions. How is the uptake of FIRDAPSE's among small cell lung cancer patients
trending? Are you seeing an impact from your patients' green efforts in this population, and how should we think about growth from small cell
lung cancer versus idiopathic patients over the next several quarters?
Question: Benjamin Paluch - Citi - Analyst
: Thank you.
Question: Joel Beatty - Baird - Analyst
: Hey, congrats on the quarter and thanks for taking the questions.
The first one is on business development activities in the past you've put a lot of focus on that.
I guess we're currently in what a lot of people are describing as a rapidly changing macro environment.
So what are your current thoughts on business development and are there any recent impacts on that?
Question: Joel Beatty - Baird - Analyst
: Great, that's helpful to hear. And then as a follow up on FIRDAPSE's for cancer associated LEMS, any anecdotes or on things that you've seen working
at a smaller scale perhaps that helps give you confidence in the strategy that you're taking to increase the diagnosis rates with the antibody and
see that lead to treatment.
Question: Joel Beatty - Baird - Analyst
: Is this something that you've maybe been able to kind of test in certain locations and trying to get into the antibody test? Are we still kind of early
in these efforts, but this is a, or maybe another way to ask is that you've had a lot of success in non-cancer associated lumps marketing, but this is
this is a different approach, so what kind of gives you confidence that you can be successful in this setting as well.
Question: Felix - Stephens - Analyst
: I'm sorry, congrats on the call. This is Felix for Sudan, Loganathan. I have a quick question on FIRDAPSE. Given the high percentage of the undiagnosed
LEMS patients.
Can you please give us color in terms of the Proportion of the penetration that you have so far on Fed up.
And what will contribute The percent penetration to increase given that you have initiative to increase diagnosis.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 08, 2025 / 12:30PM, CPRX.OQ - Q1 2025 Catalyst Pharmaceuticals Inc Earnings Call
Question: Felix - Stephens - Analyst
: No questions from my side.
Thank you very Much
| 
